Catalyst Biosciences Inc (NASDAQ:CBIO) shares have come off their early morning high of $9.00, bounced off $5.50 level and now trading above $6 handle.

Catalyst Biosciences Inc (NASDAQ:CBIO) Sees Morning Volatility

Catalyst Biosciences Inc (NASDAQ:CBIO)

Catalyst Biosciences Inc (NASDAQ:CBIO) shares have come off their early morning high of $9.00, bounced off the 45.50 level and are now trading above the $6 handle. Volume, as of 10 AM EST, is already at 1.2 million shares. CBIO shares have a listed daily average of just over 271,000. The company has released no news, or made any filings, that could account for the morning’s volatility.

Catalyst Biosciences Inc (NASDAQ:CBIO)

Catalyst Biosciences Inc. (NASDAQ:CBIO) is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. Catalyst’s most advanced program is a potent next-generation coagulation Factor VIIa variant, marzeptacog alfa (activated), that has successfully completed an intravenous Phase 1 clinical trial in individuals with severe hemophilia A or B.

CBIO Stock

In February, Catalyst Biosciences Inc. (NASDAQ:CBIO) underwent a reverse stock split to stay in compliance with NASDAQ rules regarding low priced stock. Dilution has been an issue for shareholders of CBIO. In 2013, there were 20,000 shares outstanding. By the end of 2016 that number had ballooned to 780,000.

Sales have also been going in the wrong direction. In 2012 Catalyst reported sales of $57.9 million. However, that figure was just $400,000 for FY 2016. On a diluted adjusted basis, EPS loss for 2013 was -$409.30. That loss shrank steadily and the EPS loss for CBIO was -$21.75 for 2016.

Of particular note is that the company reports a cash per share value of $6.35. Shares are trading around that level this morning. Analysts have given CBIO shares a rating of “Strong Buy”. Their consensus, one-year price target is $12.33.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Aptose Biosciences Inc (NASDAQ:APTO)

New High for Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) shares have hit a new 52-week high, are up over 17%, and trading around the $2 handle in mid-afternoon trading. Volume is heavy for the biotech’s shares as they are trading about seven times their daily average.

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) is scheduled to be releasing their Q3 2017 earnings report tomorrow, November 14, 2017, after the close of trading. According to Zacks Investment Research, the consensus of analysts are expecting an EPS loss of (-$0.13) per share.

Canadian-based Aptose Biosciences Inc (NASDAQ:APTO) is a clinical-stage biotechnology company committed that develops personalized therapies designed to address unmet medical needs in cancer patients. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer treatment. The company’s pipeline of small molecule cancer therapeutics includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

APTO Stock Performance

Shareholders of Aptose Biosciences Inc (NASDAQ:APTO) have experienced a good year. Year-to-date, APTO stock is up over 22%, and for the year the gain is an even more impressive 65%. Analysts have given APTO stock a consensus, one-year price target of $3.15. The stock’s 52-week low was established last April at a price of $0.78. Today’s price action, should it hold, will establish a new 52-week high – besting the old mark of $1.79. Given the strong upward momentum of the stock, it is not surprising that the shares have a Relative Strength score of 77 – a level that most traders consider to be a sign of an “overbought” condition.

Aptose Biosciences Inc (NASDAQ:APTO) has no reported sales. Accordingly, their earnings have been negative since 2012. In the past three years, the per share losses have expanded. In 2014 the per share loss was (-$0.53), followed the next year by (-$0.97), and (-$1.15) for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APTO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Technology, Inc. (NASDAQ:AVID) Q3 Earnings Beat Estimates

Avid Technology, Inc. (NASDAQ:AVID)

Shares of Avid Technology, Inc. (NASDAQ:AVID) gained 26.24% after the global media technology company reported better than expected Q3 2017 financial results. Revenues and bookings exceeded guidance in the quarter. Strong improvement in adjusted EBITDA allowed the company to post a fourth consecutive quarter of positive cash flow.

Avid Technology, Inc. (NASDAQ:AVID)

AVID Investors Reaction

Investors reacted to the stellar financial results by pushing the stock from this year’s lows to $5.10 a share. The stock is up by more than 10% for the year. Avid Technology, Inc. (NASDAQ:AVID) faces resistance at the $5.50 mark above which it could make a to this year’s highs of $6 a share.

Renewed investor interest in the stock is as a result of the company exceeding guidance in all its key metrics. According to Chief Executive Officer, Louis Hernandez, Jr., completion of transformation should allow Avid technology to drive profitable growth as well as increase revenue visibility and cash flow.

AVID Q3 Results

For the three months ended September 30, 2017, Avid technology bookings came above the upper end of guidance at $102.8 million. Constant currency bookings totaled $107.9 million which were in line with guidance. GAAP Revenue was $105.3 million above the upper end of guidance. Gross margin came in at 57.3%.

Net income in the quarter came in at $72,000 as adjusted free cash flow came in at $0.5 million at the upper end of the guidance. Adjusted free cash flow for the first nine months rose to $55.7 million,

According to the Chief Executive Officer, customers ranging from the largest media enterprise continue to adopt Avid Technology, Inc. (NASDAQ:AVID)’s innovative solutions.

“With our cloud-enabling MediaCentral platform, enterprises are unlocking greater strategic value from their Avid partnership as we help them to achieve new economies of scale while they work to engage audiences on any device with increasing amounts of content,” said Mr. Hernandez.

Q4 Outlook

During the quarter, Avid Technology, Inc. (NASDAQ:AVID) signed several multi-year enterprise deals with large customers, including Viacom and NHK. Total licenses for the MediaCentral platform increased 27% year-over-year to 51,000. Direct digital bookings with individual creative professionals increased 35% year-over-year.

For the fourth quarter Avid Technology, Inc. (NASDAQ:AVID) expects bookings to range between $118 and $132 million. Revenue, on the other hand, should range between $103 and $113 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q3 Net Loss Narrows

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) fell 5.36% after reporting a net loss of (-$12) million for the three months ended September 30, 2017. However, the results exceeded Wall Street expectations as revenue increased 29% compared to the second quarter.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Management remarks

The stock is currently trading at a key support level of $2.65, below which it could drop to the next support level at $2.20. BioDelivery Sciences has come under pressure in recent weeks after touching highs of $3.40 a share. Observers are keen to see if the third quarter financial results is the catalyst that will help push the stock up.

According to the Chief Executive Officer, Mark Sirgo, the solid performance in the quarter was because of the strong sales momentum behind lead product BELBUCA.

“Our solid performance in the third quarter continued the encouraging trend we have seen with BELBUCA, as we achieved prescription growth of 15% over the second quarter. The favorable trend continued into October as BELBUCA monthly total prescriptions reached an all-time high in excess of 8,000 based on preliminary sales data,” said Mr. BELBUCA.

The executive expects continued growth of BELBUCA going forward due to a new sales strategy and improved managed care involving Medicare. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has also completed an important licensing agreement with Purdue Pharma for BELBUCA.

Q3 Financial Results

Net Revenue for the three months ended September 30, 2017, came in at $11.3 million, up from $3.6 million reported in the third quarter of 2016. BELBUCA and BUNAVAIL revenue totaled $6.4 million and $1.7 million respectively. Net revenue for the first nine months of the year totaled $49.5 million compared to $11.6 million in the same period last year.

Total operating expenses for the quarter was $16.9 million compared to $16.5 million reported last year. Net loss decreased to (-$12 million) or (-$0.21) a share compared to a net loss of (-$16) million or (-$0.30) a share, reported last year. The decrease in net loss was primarily attributed to net profitability from the reacquisition of BELBUCA early in the year.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has cash and cash equivalents of $19.7 million compared to $27.5 million as of June 30, 2017. During the quarter, the company met the financial requirements needed to access the next $15 million tranche in its loan agreement with CRG.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q3 Financials Highlight Growth

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) gained 4.37% after reporting financial results for the three and nine months ended September 30, 2017. According to their Chief Executive officer, Adrian Adams, performance in the quarter underscore strength in underlying business and growth in the U.S and Canada.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

ARLZ Stock Performance

Investors’ confidence on the stock has taken a hit in recent months as seen by the stock trading in a downtrend. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is down by more than 50% for the year. It awaits to be seen if the better than expected financial results have what it takes to push the stock higher.

According to Mr. Adams, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is on the path to profitability given the performance in third quarter.

“We are delighted with the evolution of Zontivity®, the improved outlook for the Toprol-XL® franchise in the U.S. and the continued strong performance of the Canadian business. As a result of this performance, we updated our 2017 financial guidance and now expect full-year net revenue to be in the range of $95 million to $105 million,” said Mr. Adams.

Aralez Cost Cuts

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to carry out further financial reforms as part of an effort that seeks to accelerate growth heading into the year end. The efforts chould result in a leaner, yet efficient, performance oriented operating model. The improvements are geared towards streaming operations in the U.S with a view of delivering profitability that support growth.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to trim its Selling, General and Administrative expenses by $32 million or 28%, as part of a cost cutting drive. Expense reductions will include reductions in the amount of money spent on marketing, professional and consulting fees.

Aralez Q3 Financials

Revenues for the three months ended September 30, 2017 totaled $24.3 million nearly double revenues of $13.6 million reported last year. Selling General and Administrative expenses dropped to $24.7 million, from $25.4 million generated in the third quarter of last year.

Net loss in the quarter increased to (-$24.4) million or $0.37 a share, compared to a net loss of (-$20.6) million reported in Q3 2016. Aralez Pharmaceuticals exited the third quarter with cash and cash equivalent of approximately, $40.7 million, sufficient to fund operations over the next 12 months.

Buoyed by the growth phase transition, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has revised its full year outlook. The pharmaceutical company now expects revenues of between $95 million and $105 million for the full year, from an initial guidance of between $80 million and $100 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARLZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s Posts Unexpected Net Loss

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell 5.13% in after-hours trading on Thursday as investors reacted to the company’s Q3 financial results. A wider than expected net loss for the three and nine months ended September 30, 2017, appears to have spooked investors and fueled a sell-off of the stock.

DSUVIA NDA Woes

Investor confidence on the stock has hit an all-time low in the wake of the U.S. Food and Drug Administration issuing a Complete Response Letter to the company’s new drug, Dsuvia. The stock plunged to a new 52-week low of $1.95 after the regulator rejected a New Drug Application (NDA) for the drug, pending submission of additional safety data.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has shed more than 60% in market value over the past one month as investors remain skeptical about Dsuvia prospects following the FDA verdict. Disappointing Q3 financial results could accelerate the stock’s sell-off given that the company has no approved products in the market. Its growth is mostly pegged on the success of its opioid analgesics pipeline which under development.

The specialty Pharmaceutical Company has submitted an application for a Type A meeting with the FDA. The meeting is to be used to shed more light on all the requirements that the company must meet as it eyes DSUVIA NDA resubmission.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has already filed a marketing authorization application in Europe.

“DSUVIA remains our core asset as we believe the recommendations in the CRL are manageable. In addition, we successfully completed the ZALVISO Phase 3 study requested by the FDA, and remain focused on providing physicians and patients with non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings,” said CEO, Vince Angotti.

AcelRx Q3 Financial Results

For the three months ended September 30, 2017, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) generated a net loss of (-$13) million or (-$0.28) a share, compared to a net loss of (-$11.4) million generated last year. Net loss from operations totaled (-$8.9) million compared to (-$8) million during the third quarter of last year. Net Loss for the first nine months of the year increased to (-$41.4) million from (-$33.5) million as of last year.

Revenue in the quarter totaled $1.5 million made up of $1.2 million related to a collaboration with Grunenthal. Revenue for the nine months ended September 30, 2017, totaled $7.2 million. R&D and G&A expenses for the third quarter totaled $8.3 million and $28.4 million for the nine months ended September 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) Program Receives Regulatory Approval

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) traded lower after announcing the approval of its education program, ‘Diarrhea in Foals’ for veterinarians and Veterinary Technicians. Shares of the company fell 6.2% in Tuesday’s trading session to end the day at $0.161 a share.

Jaguar Health Inc. (NASDAQ:JAGX)

Diarrhea in Foals AAVSB Approval

The approval by The American Association of Veterinary State Boards (AAVSB) allows the company to offer 1.50 CE credits to each participating veterinarian or veterinary technician.

“Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care. Helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients,” said equine medical consultant Dr. Siobhan McAuliffe, MVB, DACVIM.

Tuesday’s sell-off capped yet another poor run as the stock continues to register lower lows in the market. The stock has lost more than 70% in market value since the start of the year. Jaguar Health is currently trading in a downtrend and close to its 52-week low of $0.18 a share.

Mytesi Commercialization

Jaguar Health Inc. (NASDAQ:JAGX) is a natural-products pharmaceuticals company focused on developing and commercializing novel gastrointestinal products for human and animal use. The company’s wholly-owned subsidiary develops and commercializes these products for the global marketplace. Mytesi is the company’s lead, FDA-approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.

Jaguar Health Inc. (NASDAQ:JAGX) subsidiary has launched a ‘Keep your pants on’ campaign as it seeks to raise awareness and engage with people living with HIV and Aids. The campaign seeks to provide an easy way of discussing embarrassing topics such as HIV related diarrhea.

Separately Jaguar Health carried out an underwritten public offering of 21.3 million shares of voting common stock in September. The company expects gross proceeds of $4.25 million after pricing the offering at $0.20 a share.

Jaguar Health Inc. (NASDAQ:JAGX) plans to use net proceeds from the offering for commercialization of its lead product Mytesi and for general corporate purposes as well as working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NASDAQ:ONCS

Is OncoSec Medical Inc. (NASDAQ:ONCS) A Buy?

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) traded lower following the posting of better than expected fourth quarter and full year financial results. The stock was down by 3.79% in Monday’s trading session, to end the day at $1.27 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) has gained more than 30% in market value over the past month. The impressive run has seen the stock trade above January’s trading levels after erasing a good chunk of losses accrued for the better part of the year. The stock faces immediate resistance at the $1.30 mark, above which it could make a push for the $1.52 mark.

Renewed investor interest in the stock follows the announcement that the company has made significant progress in the development of its lead clinical program ImmunoPulse IL-12. The company is developing the program for the treatment of metastatic melanoma.

During the fourth quarter, the biotechnology company presented positive Phase 2 data of ImmunoPulse IL-12, in combination with pembrolizumab.

“Our organization remains focused on advancing our PISCES/KEYNOTE-695 registration-directed trial to address this significant unmet medical need through an innovative accelerated pathway,” said CEO, Punit Dhillon.

OncoSec Q4 Financial Results

In addition to progress on the clinical development front, OncoSec Medical Inc. (NASDAQ:ONCS) is also working on trimming its net loss as it eyes positive cash flow. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million, down from (-$6.6) million reported last year. Net loss for the full year dropped to ($21.4) million from ($26.9) million.

OncoSec Medical Inc. (NASDAQ:ONCS) attributes the decrease in net loss to a $2.2 million decrease in non-cash, stock-based compensation expense and a $1.8 million decrease in Research and Development Expense. The company did not generate any revenue in the fourth quarter and full year.

The biotechnology company exited the fourth quarter with $11.4 million in cash and cash equivalent, down from $28.7 million as of July 31, 2016. The funds should finance the company’s operations through the third quarter of FY2018.

Last Month OncoSec Medical Inc. (NASDAQ:ONCS) closed a $7.1 million direct offering of 5.3 million shares of common stock, priced at $1.34 a share. The company also issued warrants for the purchase of additional shares at an exercise price of $1.25 a share.

OncoSec intends to use net proceeds of about $6.2 million for working capital and general corporate purposes such as the PISCES/KEYNOTE-695 study, among other clinical, research and development activities.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cerecor Inc (NASDAQ:CERC) Threatening New Highs

Cerecor Inc (NASDAQ:CERC)

The uptrend, that began in August, continues for Cerecor Inc (NASDAQ:CERC) stock as it looks to close at its second highest level in a year on heavy volume. The market sent shares higher after the biotechnology company released Q3 earnings this morning.

Cerecor Inc (NASDAQ:CERC)
Cerecor Inc (NASDAQ:CERC) is a biopharmaceutical company that develops drug candidates to address the needs of patients with neurologic and psychiatric disorders. Cerecor’s lead drug candidate is CERC-301, which Cerecor currently intends to explore as a treatment for orphan neurological indications. Cerecor is also developing two pre-clinical stage compounds, CERC-611 and CERC-406.

Cerecor Earnings

Cerecor, headquartered in Baltimore, MD, reported Q3 net income of $18.7 million, or $0.52 per common share, compared to a net loss of (-$6.2) million, or (-$0.70) loss per common share, for the third quarter 2016. The company reported $0.52 income per diluted common share, compared to (-$0.70) loss per diluted common share for the same period last year. Cerecor posted $25 million in license and other revenue from the sale of CERC-501 to Janssen this past August.
Q3 2017 general and administrative expenses increased to $2.2 million, compared to $1.7 million for Q3 2016. This increase was driven primarily by expenses associated with the August sale of CERC-501. As of September 30, 2017, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million.

CERC Stock Performance

Cerecor Inc (NASDAQ:CERC) shares began an uptrend after the $25 million sale of CERC-501 to Janssen Pharmaceuticals. Over the past quarter, CERC stock is up over 88%. However CERC shares were trading over $5 at the end of last year, and the drop from those levels is seen in the (-70%) performance over the past year.
Annual earnings have been disappointing for shareholders. In 2014 there was an EPS loss of (-$0.41), followed in 2015 by (-$1.22) loss, and a loss of (-$1.87) for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Market Awaits Medical Transcription Billing Corp (NASDAQ:MTBC) Earnings

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) is scheduled to release their Q3 earnings report today before the market opens. In August, the company placed its full year 2017 guidance at $31 to $32 million. That level of revenue represents a 27% to 31% growth over 2016 revenue. The company expects 2017 adjusted EBITDA to be $2.0 to $2.5 million.

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. Their platform is designed to help customers increase revenues, streamline workflows, and make better business and clinical decisions.

MTBC Stock

MTBC shares have gained over 450% year-to-date and almost 50% in just the last month. That has pushed MTBC stock from its 52-week low of $0.29, to its 52-week high, achieved in October, of $5.44.

During that time, the company repaid its debt. To pay off that debt, Medical Transcription Billing Corp (NASDAQ:MTBC) issued $7.9 million worth of Series A Preferred Stock. The move worked, according to observers, as revenues have exceeded cash operating expenses since May 2017.

Over the years, MTBC has not been able to transform annual increases in sales to profits. In 2012, the per share profit was just $0.01. Annual per share losses followed of (-$0.02), (-$0.64), (-$0.46), and, for 2016, (-$0.95).

However, sales did increase year on year. In 2012, sales were reported at $10 million. That annual figure was followed by annual figures of $10.5 million, $18.3 million, 23.1 million, and in 2016, $24.5 million.

It should be noted that the company has quite a number of short-sellers betting against it. As of November 3, 2017, over 15% of the stock’s float was being held in a short position.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MTBC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.